Nose-to-Brain Delivery of Antioxidants as a Potential Tool for the Therapy of Neurological Diseases.
antioxidants
brain targeting
nanomedicine
neurological diseases
nose-to-brain
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
21 Dec 2020
21 Dec 2020
Historique:
received:
22
11
2020
revised:
13
12
2020
accepted:
18
12
2020
entrez:
29
12
2020
pubmed:
30
12
2020
medline:
30
12
2020
Statut:
epublish
Résumé
Oxidative stress has a key role in the pathogenesis of neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases and can be an important cause of the damages in cerebral ischemia. Oxidative stress arises from high levels of reactive oxygen species (ROS). Consequently, on this rational base, antioxidants (many of natural origin) are proposed as potential drugs to prevent ROS noxious actions because they can protect the target tissues from the oxidative stress. However, the potential of antioxidants is limited, owing to the presence of the blood-brain barrier (BBB), which is difficult to cross with a consequent low bioavailability of the drug into the brain after systemic (intravenous, intraperitoneal, oral) administrations. One strategy to improve the delivery of antioxidants to the brain involves the use of the so-called nose-to-brain route, with the administration of the antioxidant in specific nasal formulations and its passage to the central nervous system (CNS) mainly through the olfactory nerve way. In the current literature, many examples show encouraging results in studies carried out in cell cultures and in animal models about the potential neuroprotective effects of antioxidants when administered through the nose. This review concerns the nose-to-brain route for the brain targeting of antioxidants as a potential tool for the therapy of neurological diseases.
Identifiants
pubmed: 33371285
pii: pharmaceutics12121246
doi: 10.3390/pharmaceutics12121246
pmc: PMC7766211
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Phytomedicine. 2007 Sep;14(9):621-7
pubmed: 17291733
Free Radic Res. 2005 Oct;39(10):1119-25
pubmed: 16298737
Int J Nanomedicine. 2014 Jun 05;9:2767-78
pubmed: 24940057
Nutrients. 2016 Oct 31;8(11):
pubmed: 27809235
Lancet. 2009 Oct 3;374(9696):1196-208
pubmed: 19801098
Exp Neurol. 2013 Nov;249:74-82
pubmed: 23994718
Brain Res. 2011 Oct 28;1420:93-105
pubmed: 21959178
Arch Neurol. 2000 Jun;57(6):824-30
pubmed: 10867779
Philos Trans R Soc Lond B Biol Sci. 2008 Aug 27;363(1504):2705-16
pubmed: 18487127
Colloids Surf B Biointerfaces. 2017 Apr 1;152:296-301
pubmed: 28126681
Curr Drug Deliv. 2012 Nov;9(6):566-82
pubmed: 22788696
J Control Release. 2015 Jun 10;207:18-30
pubmed: 25836593
Oxid Med Cell Longev. 2019 Nov 11;2019:9613090
pubmed: 31827713
Saudi J Biol Sci. 2020 Jan;27(1):500-517
pubmed: 31889876
Br J Pharmacol. 2005 Dec;146(8):1041-59
pubmed: 16205720
Basic Clin Pharmacol Toxicol. 2010 Sep;107(3):758-67
pubmed: 20406205
Int J Nanomedicine. 2012;7:3951-9
pubmed: 22866004
Mol Med Rep. 2017 Jul;16(1):908-914
pubmed: 28560379
CA Cancer J Clin. 2010 May-Jun;60(3):166-93
pubmed: 20445000
Clin Chim Acta. 2018 Oct;485:79-87
pubmed: 29940147
Nanotechnology. 2014 Dec 5;25(48):485102
pubmed: 25392203
Drug Deliv Transl Res. 2018 Oct;8(5):1460-1470
pubmed: 29785574
Curr Med Chem. 2010;17(19):2070-95
pubmed: 20423309
Colloids Surf B Biointerfaces. 2016 Nov 1;147:376-386
pubmed: 27566226
Ann N Y Acad Sci. 2011 Jan;1215:103-8
pubmed: 21261647
Free Radic Biol Med. 2006 May 15;40(10):1776-84
pubmed: 16678015
J Neurosci Res. 2004 Mar 15;75(6):742-50
pubmed: 14994335
J Clin Pharmacol. 2000 Jul;40(7):781-4
pubmed: 10883420
Pharmaceutics. 2019 Mar 03;11(3):
pubmed: 30832389
Molecules. 2018 Dec 11;23(12):
pubmed: 30544977
J Neurochem. 2004 Nov;91(3):755-65
pubmed: 15485504
Drug News Perspect. 1998 Jun;11(5):291-6
pubmed: 15616649
Neural Regen Res. 2018 Dec;13(12):2102-2104
pubmed: 30323136
Neuropharmacology. 2014 Apr;79:380-8
pubmed: 24333330
Drug Deliv. 2008 Aug;15(6):381-8
pubmed: 18686082
Cancer Res. 2006 Jan 15;66(2):1081-8
pubmed: 16424044
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Drug Deliv. 2016 May;23(4):1444-52
pubmed: 26401600
Toxicol Lett. 2018 Jan 5;282:100-108
pubmed: 29097221
J Control Release. 2015 Mar 10;201:68-77
pubmed: 25620068
Neuropharmacology. 2001 Jun;40(8):959-75
pubmed: 11406187
Biomed Res Int. 2019 Apr 14;2019:2382563
pubmed: 31111044
Oncology. 1996 Jan-Feb;53(1):43-6
pubmed: 8570130
J Neurochem. 2003 Jun;85(5):1101-8
pubmed: 12753069
J Alzheimers Dis. 2015;44(3):897-906
pubmed: 25374101
Biochim Biophys Acta. 2012 Jul;1820(7):940-8
pubmed: 22503788
Mol Neurobiol. 2016 Aug;53(6):4094-4125
pubmed: 26198567
J Drug Target. 2011 Nov;19(9):731-40
pubmed: 21428693
J Pharm Sci. 2018 Apr;107(4):1143-1156
pubmed: 29183742
Drug Dev Ind Pharm. 2019 Oct;45(10):1624-1634
pubmed: 31353967
Int J Biol Macromol. 2016 Jul;88:320-32
pubmed: 26976069
Eur J Pharm Biopharm. 2017 Mar;112:58-66
pubmed: 27865856
Biochem Biophys Res Commun. 2003 Oct 3;309(4):1017-26
pubmed: 13679076
J Neurochem. 2007 Aug;102(4):1095-104
pubmed: 17472706
Mol Ther. 2011 Oct;19(10):1769-79
pubmed: 21915101
Carbohydr Polym. 2018 Nov 1;199:572-582
pubmed: 30143164
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):12-26
pubmed: 16938373
Int J Biol Macromol. 2018 Apr 1;109:27-35
pubmed: 29247729
Biomed Pharmacother. 2017 Feb;86:441-449
pubmed: 28012923
Arch Neurol. 1975 Feb;32(2):114-8
pubmed: 1122174
Nanomedicine (Lond). 2011 Sep;6(7):1215-30
pubmed: 21449849
Int J Pharm. 2016 Nov 20;513(1-2):280-293
pubmed: 27633279
Int J Biol Macromol. 2016 Oct;91:640-55
pubmed: 27264648
Ann Indian Acad Neurol. 2008 Jan;11(1):13-9
pubmed: 19966973
Pharmazie. 2010 May;65(5):379-83
pubmed: 20503933
Pharmazie. 2002 Dec;57(12):820-4
pubmed: 12561244
Drug Dev Ind Pharm. 2019 May;45(5):839-851
pubmed: 30702966
Endocr Res. 2004 Aug;30(3):455-67
pubmed: 15554361
J Agric Food Chem. 2009 Sep 9;57(17):7700-5
pubmed: 19658402
Pharmaceutics. 2018 Dec 29;11(1):
pubmed: 30597930
J Neurosci. 1997 Mar 1;17(5):1683-90
pubmed: 9030627
Curr Drug Targets. 2017 Mar 30;18(6):705-718
pubmed: 27033198
AAPS PharmSciTech. 2019 May 2;20(5):181
pubmed: 31049748
Neurobiol Dis. 2009 Mar;33(3):429-35
pubmed: 19110057
Neurology. 2015 Oct 20;85(16):1383-91
pubmed: 26362286
J Alzheimers Dis. 2017;59(3):961-974
pubmed: 28731428
Integr Cancer Ther. 2008 Sep;7(3):189-203
pubmed: 18815150
Life Sci. 2018 Feb 15;195:44-52
pubmed: 29277310
Pharmaceutics. 2019 Feb 17;11(2):
pubmed: 30781585
Pharm Res. 2019 Jul 1;36(9):131
pubmed: 31263962
Biochem Biophys Res Commun. 2013 Jun 7;435(3):361-6
pubmed: 23669037
J Biol Chem. 1998 Mar 27;273(13):7185-8
pubmed: 9516407
J Pharm Pharmacol. 2006 Nov;58(11):1459-65
pubmed: 17132208
Pharmacol Res. 2015 Sep;99:1-10
pubmed: 25982933
Neurochem Int. 2019 Jan;122:47-58
pubmed: 30439384
J Pharm Sci. 2011 Apr;100(4):1488-502
pubmed: 24081472
Neuroscience. 2013 Dec 19;254:379-94
pubmed: 24070629
Food Chem. 2013 Jun 15;138(4):2099-107
pubmed: 23497863
Int J Pharm. 2018 May 30;543(1-2):214-223
pubmed: 29605695
Stroke. 1996 Jun;27(6):1124-9
pubmed: 8650725
Drug Deliv. 2015;22(7):931-9
pubmed: 24512295
Brain Sci. 2019 Oct 15;9(10):
pubmed: 31618942
J Alzheimers Dis. 2002 Dec;4(6):517-22
pubmed: 12629261
Eur J Pharm Biopharm. 2018 Jun;127:250-259
pubmed: 29486302
J Agric Food Chem. 2005 Jun 15;53(12):4740-6
pubmed: 15941309